FDA panel votes 8-3 Regeneron's (REGN) Arcalyst unsafe in gout flares
Tweet
Share
E-mailGet Alerts REGN Hot Sheet
Join SI Premium – FREE
FDA panel votes 8-3 Regeneron's (Nasdaq: REGN) Arcalyst unsafe in gout flares
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- FDA approves Regeneron's Pasatru for rare bone disorder FOP
- Sigma Lithium resumes full operations after signing TAC agreement
- Kimbell Royalty closes $221.2M mineral rights acquisition
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
